Deferred Income Tax Expense (Benefit) of Indivior Pharmaceuticals, Inc. from 31 Dec 2022 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary: Indivior Pharmaceuticals, Inc. annual and quarterly Deferred Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2022 to 31 Dec 2025.
Indivior Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending 31 Mar 2025 was $2,000,000, a 167% decline year-over-year.
Indivior Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2025 was $46,000,000, a 757% decline from 2024.
Indivior Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $7,000,000.
Indivior Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $64,000,000, a 38% increase from 2022.
Source SEC data: View on sec.gov

Deferred Income Tax Expense (Benefit), Annual (USD)

Deferred Income Tax Expense (Benefit), YoY Annual Change (%)

Deferred Income Tax Expense (Benefit), Quarterly (USD)

Deferred Income Tax Expense (Benefit), YoY Quarterly Change (%)

Indivior Pharmaceuticals, Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2025	$46,000,000	-$53,000,000	-757%	01 Jan 2025	31 Dec 2025	10-K	26 Feb 2026	2025	FY
2024	$7,000,000	+$71,000,000		01 Jan 2024	31 Dec 2024	10-K	26 Feb 2026	2025	FY
2023	$64,000,000	+$40,000,000	+38%	01 Jan 2023	31 Dec 2023	10-K	26 Feb 2026	2025	FY
2022	$104,000,000			01 Jan 2022	31 Dec 2022	10-Q	30 Oct 2025	2025	Q3

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2025		$2,000,000	-$5,000,000	-167%	01 Jan 2025	31 Mar 2025	10-Q	01 May 2025	2025	Q1
Q1 2024		$3,000,000			01 Jan 2024	31 Mar 2024	10-Q	01 May 2025	2025	Q1

* An asterisk sign (*) next to the value indicates that the value is likely invalid.